Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

This invention relates to compounds of Formula (I):and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and...

Full description

Saved in:
Bibliographic Details
Main Authors Ellis, Bryan Daniel, Hicken, Erik James, Lazzara, Nicholas Charles, Boys, Mark Laurence, Pajk, Spencer Phillip, Gaudino, John Joseph, Laird, Ellen Ruth, Newhouse, Bradley Jon
Format Patent
LanguageEnglish
Published 05.12.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:This invention relates to compounds of Formula (I):and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
Bibliography:Application Number: US202117362580